Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is being evaluated clinically for cancer therapy, selectively induces apoptosis in tumor cell lines without causing toxicity to normal cells. However, its therapeutic potential is limited by occurring resistance in a majority of lung carcinoma, breast and prostate cells. Various chemotherapeutic drugs have been found to enhance TRAIL-induced apoptosis. The objective of this study was to examine whether non-small cell lung cancer (NSCLC) cell line A-549, one of the most drug-resistant tumor cells in human, can be sensitized by doxorubicin (DOX) to TRAIL-mediated apoptosis. We show that DOX and recombinant human TRAIL (TRAIL) have a synergistic cytotoxic effect against A-549 cells in vitro. However, no obvious antitumor effects were observed in A-549 tumor bearing nude mice treated by TRAIL alone, DOX alone or both agents, suggesting that further works should be carried to improve the efficacy of combined treatment of DOX and TRAIL.
Keywords: Apoptosis, A-549 cell lines, Combined treatment, Doxorubicin, Non-Small Cell Lung Cancer, TRAIL, DU-145 cell lines, DOX, NSCLC, therapeutic plateau, angiogenesis, necrosis, tumor, caspases
Letters in Drug Design & Discovery
Title: Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Volume: 8 Issue: 9
Author(s): Li Fan, Liangran Guo, Jinfeng Ren, Yulong Ren, Zhiqing Pang and Xinguo Jiang
Affiliation:
Keywords: Apoptosis, A-549 cell lines, Combined treatment, Doxorubicin, Non-Small Cell Lung Cancer, TRAIL, DU-145 cell lines, DOX, NSCLC, therapeutic plateau, angiogenesis, necrosis, tumor, caspases
Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is being evaluated clinically for cancer therapy, selectively induces apoptosis in tumor cell lines without causing toxicity to normal cells. However, its therapeutic potential is limited by occurring resistance in a majority of lung carcinoma, breast and prostate cells. Various chemotherapeutic drugs have been found to enhance TRAIL-induced apoptosis. The objective of this study was to examine whether non-small cell lung cancer (NSCLC) cell line A-549, one of the most drug-resistant tumor cells in human, can be sensitized by doxorubicin (DOX) to TRAIL-mediated apoptosis. We show that DOX and recombinant human TRAIL (TRAIL) have a synergistic cytotoxic effect against A-549 cells in vitro. However, no obvious antitumor effects were observed in A-549 tumor bearing nude mice treated by TRAIL alone, DOX alone or both agents, suggesting that further works should be carried to improve the efficacy of combined treatment of DOX and TRAIL.
Export Options
About this article
Cite this article as:
Fan Li, Guo Liangran, Ren Jinfeng, Ren Yulong, Pang Zhiqing and Jiang Xinguo, Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo, Letters in Drug Design & Discovery 2011; 8 (9) . https://dx.doi.org/10.2174/157018011797200867
DOI https://dx.doi.org/10.2174/157018011797200867 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Indole Derivatives as Anticancer Agents for Breast Cancer Therapy: A Review
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Current Drug Targets Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Chronic Inflammatory Diseases and the Acute Respiratory Distress Syndrome (ARDS)
Current Pharmaceutical Design Benzamide Riboside, a Recent Inhibitor of Inosine 5-Monophosphate Dehydrogenase Induces Transferrin Receptors in Cancer Cells
Current Medicinal Chemistry Aspartic Proteases in Drug Discovery
Current Pharmaceutical Design Antioxidant Vitamins and Cardiovascular Disease
Current Topics in Medicinal Chemistry Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1
Anti-Cancer Agents in Medicinal Chemistry Advances in Photodynamic Therapy of Cancer
Current Cancer Therapy Reviews Two Identical Twin Nitrogen Mustard Agents that Express Rapid Alkylation Activity at Physiological pH 7.4 and 37°C
Letters in Drug Design & Discovery Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor
Current Drug Targets Investigation into the Formation Mechanism and Distribution Characteristics of Suspended Microparticles in MQL Grinding
Recent Patents on Mechanical Engineering PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Biological Evaluation of Scutellaria Flavone Cyclaneaminol Mannich Base Derivatives as Novel CDK1 Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Mitigative Effects of a Combination of Multiple Pharmaceutical Drugs on the Survival of Mice Exposed to Lethal Ionizing Radiation
Current Pharmaceutical Biotechnology A Comprehensive Review on Exosomes and Microvesicles as Epigenetic Factors
Current Stem Cell Research & Therapy Antitumor Activity of Polysaccharides: An Overview
Current Drug Targets Malignancy Risk in Systemic Lupus: Recent Research and Ongoing Challenges
Current Rheumatology Reviews Antitumoral Potential of Snake Venom Phospholipases A2 and Synthetic Peptides
Current Pharmaceutical Biotechnology